aTYR PHARMA INC - 8-K Filing
aTyr Pharma reported $68.3 million in cash, cash equivalents, restricted cash, and available-for-sale investments as of March 31, 2026. The company announced plans to initiate a new Phase 3 trial for efzofitimod in pulmonary sarcoidosis following an FDA Type C meeting, with the study expected to begin dosing patients after submitting an IND application in June 2026. (Items: 2.02 Results of Operations and Financial Condition, 7.01 Regulation FD Disclosure, 8.01 Other Events, 9.01 Financial Statements and Exhibits)
Tickers: $ATYR